LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Mustafa Özgüroğlu, Saadettin Kılıçkap, A. Sezer, M. Gumus, Igor Bondarenko, M. Gogishvili, Marina Nechaeva, M. Schenker, I. Cicin, Gwo Fuang Ho, Y. Kulyaba, Mikhail Dvorkin, K. Zyuhal, R.I. Scheusan, S. Li, J-F. Pouliot, Frank Seebach, I. Lowy, G. Gullo, Petra Rietschel